2023.12.27
Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
An article about the research results of Dr. Masayuki Nakamori (Neurology), Division of Advanced Cell Therapy, was posted on the University’s website.
Please click the following link for details.
筋強直性ジストロフィーに対する世界初の根本的治療薬開発 ～医師主導第二相治験により有効性を支持する成果～｜国立大学法人山口大学HP